BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» FDA lambastes payment model and its impact on U.S. 'anemic' biosimilar market
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
FDA lambastes payment model and its impact on U.S. 'anemic' biosimilar market
July 20, 2018
By
Mari Serebrov
No Comments
FDA Commissioner Scott Gottlieb hammered home what could become another nail in the coffin for prescription drug rebates as he laid out a Biosimilar Action Plan intended to enliven what he called an anemic U.S. biosimilar market.
BioWorld